From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 364-370

  Zheng, H ^a   Fridkin, M ^b   Youdim, M B H ^c,d  

^a Intra Cellular Therapies Inc   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Yonsei University   (South Korea)

Author keywords

AChE MAO A B Inhibitors; Alzheimer's Disease; HLA20; HLA20A; M30; M30D; Multi Target Chelators; Site Activated

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; CHELATING AGENT; DIMERCAPROL; HLA 20; HLA 20 A; HYPOXIA INDUCIBLE FACTOR 1; LADOSTIGIL; M 30 D; PBT 2; RASAGILINE; TETRATHIOMOLYBDIC ACID; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DRUG DESIGN; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW;

EID: 84860290271     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800493898     Document Type: Review

References (40)

1. Extance, A. Alzheimer's failure raises questions about disease- modifying strategies. Nat. Rev. Drug Discov., 2010, 9, 749-751.
2. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
3. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4, 682-690.
4. Atri, A.; Shaughnessy, L.W.; Locascio, J.J.; Growdon, J.H. Longterm course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2008, 22, 209-21.
5. Chow, V.W.; Savonenko, A.V.; Melnikova, T.; Kim, H.; Price, D.L.; Li, T.; Wong, P.C. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci. Transl. Med., 2010, 2, 13ra1.
6. Lehar, J.; Krueger, A.S.; Avery, W.; Heilbut, A.M.; Johansen, L.M.; Price, E.R.; Rickles, R.J.; Short, G.F., 3rd; Staunton, J.E.; Jin, X.; Lee, M.S.; Zimmermann, G.R.; Borisy, A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol., 2009, 27, 659-666.
7. Anttila, S.A.; Leinonen, E.V. A review of the pharmacological and clinical profile of mirtazapine. CNS drug reviews, 2001, 7, 249-264.
8. Williams, T.I.; Lynn, B.C.; Markesbery, W.R.; Lovell, M.A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging, 2006, 27, 1094-1099.
9. Guglielmotto, M.; Giliberto, L.; Tamagno, E.; Tabaton, M. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci, 2010, 2, 3.
10. Duce, J.A.; Bush, A.I. Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics. Prog. Neurobiol., 2010.
11. Rogers, J.T.; Randall, J.D.; Cahill, C.M.; Eder, P.S.; Huang, X.; Gunshin, H.; Leiter, L.; McPhee, J.; Sarang, S.S.; Utsuki, T.; Greig, N.H.; Lahiri, D.K.; Tanzi, R.E.; Bush, A.I.; Giordano, T.; Gullans, S.R. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem., 2002, 277, 45518-45528.
12. Friedlich, A.L.; Tanzi, R.E.; Rogers, J.T. The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry, 2007, 12, 222-223.
13. Rogers, J.T.; Mikkilineni, S.; Cantuti-Castelvetri, I.; Smith, D.H.; Huang, X.; Bandyopadhyay, S.; Cahill, C.M.; Maccecchini, M.L.; Lahiri, D.K.; Greig, N.H. The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J. Neural Transm., 2011, 118, 493-507.
14. Davies, P.; Moualla, D.; Brown, D.R. Alpha-synuclein is a cellular ferrireductase. PLoS ONE, 2011, 6, e15814.
15. Duce, J.A.; Tsatsanis, A.; Cater, M.A.; James, S.A.; Robb, E.; Wikhe, K.; Leong, S.L.; Perez, K.; Johanssen, T.; Greenough, M.A.; Cho, H.H.; Galatis, D.; Moir, R.D.; Masters, C.L.; McLean, C.; Tanzi, R.E.; Cappai, R.; Barnham, K.J.; Ciccotosto, G.D.; Rogers, J.T.; Bush, A.I. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 2010, 142, 857-867.
16. Payton, S.; Cahill, C.M.; Randall, J.D.; Gullans, S.R.; Rogers, J.T. Drug discovery targeted to the Alzheimer's APP mRNA 5'- untranslated region: the action of paroxetine and dimercaptopropanol. J. Mol. Neurosci., 2003, 20, 267-275.
17. Zheng, H.; Weiner, L.M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z.I.; Warshawsky, A.; Youdim, M.B.; Fridkin, M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem., 2005, 13, 773-783.
18. Youdim, M.B.F.M.; Zheng, H.; Warshawsky, A.; Warshawsky, R. Neuroprotective iron chelators and pharmaceutical compositions comprising them. U.S. Patent 0,234,927, A1, OCT. 19, 2006.
19. Schugar, H.; Green, D.E.; Bowen, M.L.; Scott, L.E.; Storr, T.; Bohmerle, K.; Thomas, F.; Allen, D.D.; Lockman, P.R.; Merkel, M.; Thompson, K.H.; Orvig, C. Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angew. Chem. Int. Ed. Engl., 2007, 46, 1716-1718.
20. Choi, J.S.; Braymer, J.J.; Nanga, R.P.; Ramamoorthy, A.; Lim, M.H. Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 21990-21995.
21. Faux, N.G.; Ritchie, C.W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C.L.; Tanzi, R.E.; Cummings, J.L.; Herd, C.M.; Bush, A.I. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J. Alzheimers Dis., 2010, 20, 509-516.
22. Shachar, D.B.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharma-cology, 2004, 46, 254-263.
23. Zhu, W.; Xie, W.; Pan, T.; Xu, P.; Fridkin, M.; Zheng, H.; Jankovic, J.; Youdim, M.B.; Le, W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J., 2007, 21, 3835-3844.
24. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol., 2010, 92, 330-344.
25. Zheng, H.; Gal, S.; Weiner, L.M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem., 2005, 95, 68-78.
26. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H.; Fridkin, M.; Youdim, M.B. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem., 2007, 100, 490-502.
27. Kupershmidt, L.; Weinreb, O.; Amit, T.; Mandel, S.; Carri, M.T.; Youdim, M.B. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J., 2009, 23, 3766-3779.
28. Saura, J.; Luque, J.M.; Cesura, A.M.; Da Prada, M.; Chan-Palay, V.; Huber, G.; Loffler, J.; Richards, J.G. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience, 1994, 62, 15-30.
29. Reinikainen, K.J.; Soininen, H.; Riekkinen, P.J. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J. Neurosci. Res., 1990, 27, 576-586.
30. Olanow, C.W.; Rascol, O.; Hauser, R.; Feigin, P.D.; Jankovic, J.; Lang, A.; Langston, W.; Melamed, E.; Poewe, W.; Stocchi, F.; Tolosa, E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med., 2009, 361, 1268-1278.
31. Gal, S.; Zheng, H.; Fridkin, M.; Youdim, M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem., 2005, 95, 79-88.
32. Gal, S.; Abassi, Z.A.; Youdim, M.B. Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox. Res., 2010, 18, 143-150.
33. Inestrosa, N.C.; Alvarez, A.; Perez, C.A.; Moreno, R.D.; Vicente, M.; Linker, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcho-linesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891.
34. Youdim, M.B.F.M.; Zheng, H. Neuroprotective multifunctional compounds and pharmacceutical compositions comprising them. WO 086,860, May 8, 2010.
35. Zheng, H.; Youdim, M.B.; Fridkin, M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J. Med. Chem., 2009, 52, 4095-4098.
36. Zheng, H.; Youdim, M.B.; Fridkin, M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol., 2010, 5, 603-610.
37. Weinstock, M.; Luques, L.; Bejar, C.; Shoham, S. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J. Neural Transm. Suppl., 2006, 443-446.
38. Correia, S.C.; Moreira, P.I. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J. Neurochem., 2010, 112, 1-12.
39. Avramovich-Tirosh, Y.; Bar-Am, O.; Amit, T.; Youdim, M.B.; Weinreb, O. Up-regulation of hypoxia-inducible factor (HIF) -1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res., 2010, 7, 300-306.
40. Kupershmidt, L.; Weinreb, O.; Amit, T.; Mandel, S.; Bar-Am, O.; Youdim, M.B. Novel molecular targets of the neuroprotective/ neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience, 2011.